You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Administrative Supplement to restore fee funds

    SBC: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC.            Topic: NINDS

    Project Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. A Novel Therapeutic that Harnesses MIcrotubules to Enhance Corneal Wound Healing Following an Alkaline Burn

    SBC: MICROCURES INC            Topic: NEI

    The cornea is one of the most important tissues in the eye and its transparency is critical for good visual function in humansCorneal tissue injuries are the most common everyday issue for practicing ophthalmologists and can run the gamut in severityIn severe modelssuch as corneal alkaline burnsextensive healing is needed and often the burn victim is left with reduced visual acuityHealing of large ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease

    SBC: NEURODON, LLC            Topic: NIA

    Alzheimer s diseaseADis an immense national public health burdenIt is theth leading cause of death in the US with overmillion Americans sufferingand costs of over $billion in health care and related expensesThis patient population is expected to almost triple over the nextyearsDespite this urgent needthere are currently no disease modifying agents approvedNeuron loss is the only physiological phen ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Pirenzepine for CIPN

    SBC: WinSanTor, Inc.            Topic: NCI

    PROJECT SUMMARY Chemotherapy induced peripheral neuropathyCIPNis a debilitating condition that afflictsof cancer patients undergoing chemotherapy and limits the dose and duration of treatmentSymptoms range from sensory loss to painful neuropathy and are accompanied by electrophysiological and structural indices of nerve damageThe American Society of Clinical Oncology currently makes no recommendat ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. O-Glycan-dependent Immunotherapy for Cancer

    SBC: GLYTR THERAPEUTICS, INC.            Topic: 102

    Abstract For decadesthe treatment of cancer has relied on surgical resectionchemotherapy and or radiotherapyRecentlya number of immune based therapies have provided promising new approaches for cancer treatmentThe two most potent immunotherapies are monoclonal antibodymABbased bi specific proteinseg Bispecific T cell engagersBiTEand engineered Chimeric Antigen Receptor T cellsCAR TBoth act by indu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Deriving Bone Density from Thoracic CT Scans, STTR Phase II

    SBC: BDI, Inc.            Topic: NIAMS

    ABSTRACT Osteoporosis is a major cause of disability and morbidity in our populationAs many asmillion Americans have osteoporosis andmillion more have osteopeniaHoweverbone mineral densityBMDassessment does not occur in many Americans when indicated and measure currently requires a separate referral and separate imaging scan to obtain BMDThe result is that onlyof Americans who are at risk of suffe ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Clinical Screening Platform for Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    AbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. The Microscopic Imaging of Epigenetic Landscape- NeuroDevelopment (MIEL-ND) assay: a high throughput platform to screen compounds for neurodevelopmental effects

    SBC: VALA SCIENCES, INC.            Topic: 101

    Neurodevelopmental diseasesNDDsAutism Spectrum DisorderASDIntellectual DisabilitiesBipolar disordersand Schizophreniaetcare prevalent and due to errors in neurodifferentiation and neurocircuitryWhile NDDsin many casesare due to inherited mutationsevidence is mounting that prenatal exposure to environmental toxicants also cause NDDs via disruption of epigeneticse gmodifications of histoneshistone t ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Clinical Translation of a Caveolae Targeting Antibody for Enhancing Cancer Drug Delivery

    SBC: Cavatar LLC            Topic: NCI

    PROJECT SUMMARY This proposal aims to develop a novel caveolae targeting antibody for rapid clinical translationIts long term objective is to develop the caveolae pumping systeman active transendothelial transport pathwayto provide an effective solution to the delivery and toxicity problem of systemically administered chemotoxinsWork will be based on the current proprietary mouse monoclonal antibo ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Evaluating Synthetic Biology Produced Triterpene Oils in Adjuvant Formulations

    SBC: Enepret Incorporated            Topic: NIAID

    ABSTRACT Vaccine adjuvants help stimulate the body to generate an immune response when co injected with an antigenthe compound for which immunity is desiredAlthough the human body is capable of producing antibodies to most injected antigensadjuvants can help boost the body s ability to mount a successful and acquired immune response to the presented targetAdjuvants have been shown to enhance immun ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government